News
LENZ
3.915
+5.24%
0.195
LENZ Therapeutics: Below Cash For A Reason
Seeking Alpha · 2d ago
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Seeking Alpha · 3d ago
Gene editing stocks fall after report on Anthropic’s CRISPR-like discovery
Seeking Alpha · 4d ago
Weekly Report: what happened at LENZ last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at LENZ last week (0907-0911)?
Weekly Report · 09/14 10:16
Weekly Report: what happened at LENZ last week (0831-0904)?
Weekly Report · 09/07 10:10
LENZ Therapeutics: Still Speculative But Priced For Disasters
Seeking Alpha · 09/04 14:41
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Seeking Alpha · 09/02 14:15
Weekly Report: what happened at LENZ last week (0824-0828)?
Weekly Report · 08/31 10:17
Weekly Report: what happened at LENZ last week (0817-0821)?
Weekly Report · 08/24 10:17
Lenz Therapeutics Balances Early Traction with Heavy Losses
TipRanks · 08/24 00:09
LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/19 13:55
Weekly Report: what happened at LENZ last week (0810-0814)?
Weekly Report · 08/17 10:18
Lenz Therapeutics price target lowered to $10 from $20 at Citi
TipRanks · 08/17 10:06
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83
Simply Wall St · 08/14 12:07
Lenz drops as BofA downgrades on a slower VIZZ launch
Seeking Alpha · 08/13 16:40
LENZ Therapeutics (LENZ) Stock Reflects Loss Fatigue Despite Long Cash Runway
Simply Wall St · 08/13 03:38
LENZ Therapeutics Is Maintained at Neutral by Piper Sandler
Dow Jones · 08/12 16:34
LENZ Therapeutics Price Target Cut to $7.00/Share From $12.00 by Piper Sandler
Dow Jones · 08/12 16:34
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Benzinga · 08/12 16:24
More
Webull provides a variety of real-time LENZ stock news. You can receive the latest news about LENZ THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.